Investing News NetworkMAR 274 min read$INM

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Inc. (NASDAQ: INM) announced it received a notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement for continued listing. The company's common stock traded below this threshold for 30 consecutive trading days between February 11, 2026, and March 26, 2026. InMed has 180 calendar days to regain compliance, and its shares will continue to trade on The Nasdaq Capital Market under the symbol "INM" while it explores options to cure the deficiency.

Original reporting

Investing News Network · Investing News Network

Published Mar 27, 2026, 9:52 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Mar 27, 2026, 10:31 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance — source image — Source · Investing News Network

Decision brief

The 30-second read

$INMBearishMed

Why it matters

This development introduces short-term bearish pressure on INM, with possible long-term recovery if the company addresses the compliance issue effectively.

Market read

High relevance for traders holding or considering trading INM, with sector-wide implications for biotech stocks on Nasdaq.

What to watch

Potential for company to seek a reverse stock split or other measures to maintain listing, which could influence stock performance positively.

Timing: Immediate, as the compliance issue is current and ongoing.

Background

InMed Pharmaceuticals has been notified by Nasdaq for failing to meet the minimum bid price requirement, risking delisting.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$INMBearishMedium confidence

Context

High relevance due to direct impact from Nasdaq compliance issue.

Expected impact

Potential short-term decline followed by possible recovery if compliance is achieved.

Evidence & confidence

The breach of Nasdaq listing requirements often leads to negative market sentiment and stock price volatility. The company's efforts to regain compliance could stabilize or improve the stock price over time.

Market effects

Sector

Potential negative impact on biotech and life sciences sectors due to increased scrutiny of Nasdaq-listed companies.

Regional

Limited regional impact, primarily affecting US markets.

Global

Minimal global relevance beyond US-based investors and biotech sector.

Counterpoint

What could challenge this read

The company may successfully regain compliance within the 180-day window, leading to a rebound in stock price.

Key entities

Exchange
Nasdaq
The stock exchange that issued the compliance notice.
Company
InMed Pharmaceuticals
The subject of the compliance notification.

Read at source ← All news

JUL 22

$INMMed

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - InMed Pharmaceutica

Mentari Therapeutics raised an additional $200 million via a private placement ahead of its planned merger with InMed Pharmaceuticals (NASDAQ:INM). The deal also closes alongside a previously announced $290 million private placement. Funds extend Mentari’s cash runway into 2029 to support Phase 2a readouts for PACAP-targeted programs, including MT-002. Post-merger, the company will trade on Nasdaq under a new ticker.

benzinga.com4 min

JUL 22

$INMMedAI 8/10

InMed Shares Rise Pre-Market On Mentari's $200 Million Financing Ahead Of Merger

InMed Pharmaceuticals (INM) rose in pre-market after merger partner Mentari Therapeutics announced a $200 million private placement of common stock and pre-funded warrants. Mentari said the funds extend its runway to 2029 and support Phase 2a readouts for PACAP programs, including MT-002. The all-stock merger with InMed is expected to close in 2H 2026.

rttnews.com3 min

JUL 6

$INMMed

InMed Pharmaceuticals: InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4

InMed Pharmaceuticals (NASDAQ: INM) said it amended a previously announced all-stock merger agreement with privately held Mentari Therapeutics and its merger subsidiaries. InMed filed a preliminary Form S-4 with the SEC for the deal. The boards approved; closing is expected in Q4 2026, pending shareholder approvals and S-4 effectiveness.

finanznachrichten.de3 min

JUN 4

$INMMedAI 8/10

InMed Pharmaceuticals: InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements

InMed Pharmaceuticals (NASDAQ: INM) said Nasdaq notified it on June 3, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its closing bid stayed at or above $1.00 for 10 straight business days (May 19–June 2). Nasdaq had flagged a failure to meet the $1.00 minimum for 30 days ending March 27. Nasdaq said the matter is closed.

finanznachrichten.de4 min

AUG 9

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

baystreet.ca3 min